Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy

Am J Ophthalmol. 2003 Mar;135(3):285-90. doi: 10.1016/s0002-9394(02)01970-0.

Abstract

Purpose: To report the effect of high-dose intravenous corticosteroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy.

Design: Nonrandomized clinical trial.

Methods: We selected 39 Japanese patients (age range, 22-64 years; mean, 48 years; 31 women, 8 men) who had active Graves' ophthalmopathy among 195 consecutive patients. In the first 20 patients, high-dose intravenous methylprednisolone pulse therapy (1 g per day for 3 successive days, repeated 3 times within 3 weeks) followed by 24-Gy orbital radiotherapy was performed. In the other 19 of the 39 patients, high-dose intravenous methylprednisolone pulse therapy without orbital radiotherapy was performed. Coronal computed tomography (CT) of the orbit and exophthalmometry were performed before the corticosteroid pulse therapy, and 1 and 6 months after the corticosteroid pulse therapy. The maximum coronal section area of the most hypertrophic rectus muscle in each eye was measured based on orbital CT imaging.

Results: Clinical findings at study entry were not significantly different between the two groups. No significant difference was found in the maximum coronal section area of the most hypertrophic rectus muscle and the results of exophthalmometry measurements in both groups before the therapy. Extraocular muscle hypertrophy was significantly reduced 1 month and 6 months after the therapy (P < .01) in both groups. However, no beneficial therapeutic effect on proptosis was observed in either group at 1 month and 6 months after the therapy. No significant difference in the therapeutic effect on extraocular muscle hypertrophy and proptosis was found between the two groups.

Conclusions: Orbital irradiation after corticosteroid pulse therapy had no beneficial therapeutic effects on rectus muscle hypertrophy or proptosis of active Graves' ophthalmopathy during the 6-month follow-up period.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Female
  • Glucocorticoids / administration & dosage*
  • Graves Disease / diagnostic imaging
  • Graves Disease / drug therapy*
  • Graves Disease / radiotherapy*
  • Humans
  • Hypertrophy
  • Injections, Intravenous
  • Male
  • Methylprednisolone / administration & dosage*
  • Middle Aged
  • Oculomotor Muscles / diagnostic imaging
  • Oculomotor Muscles / pathology
  • Orbit / diagnostic imaging
  • Orbit / radiation effects*
  • Pulse Therapy, Drug
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Methylprednisolone